Browsing: Obesity & Weight Management

Evidence summaries for obesity and weight management, including lifestyle trials, pharmacotherapy, bariatric/metabolic outcomes, cardiometabolic risk, and long-term safety.

All

UKPDS 34 demonstrated that metformin reduces diabetes-related endpoints, death, and all-cause mortality by 32–42% in overweight patients with newly diagnosed type 2 diabetes, with superior cardiovascular outcomes compared with sulphonylurea or insulin, establishing metformin as the preferred first-line pharmacological therapy for type 2 diabetes for the subsequent three decades.